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Study Importance Questions 
 
1. What major reviews have already been published on this subject? 
 
a) Loos, R.J.F. (2012) Genetic determinants of common obesity and their value in prediction, 
Best Practice & Research Clinical Endocrinology & Metabolism, 26(2): 211-226.   
This paper reviews the discovery of loci associated with obesity-related traits, and 
subsequently focuses on the body mass index (BMI) loci in particular to explore whether 
there is sufficient evidence for these loci to be used as clinical predictors.  It does not 
consider use of loci in causal analyses. 
 
b) Burgess, S. et al. (2015) Mendelian randomization: where are we now and where are we 
going? International Journal of Epidemiology, 44(2): 378-388. 
This editorial considers developments in the methodology and application of Mendelian 
randomization to study causal mechanisms in health and disease over the past decade.  It 
does not consider adiposity, BMI or obesity specifically. 
 
2. What does our study add? 
 
Progress in the field of applied genetic epidemiology and in particular in the application of 
Mendelian randomisation has been rapid in the last few years, driven largely by developments in a 
variety of omics technologies.  This review provides a reflection on what has been achieved so far 
in dissecting the causal relationship between body mass index (BMI) and disease and gives 
comment on the likely future directions of this field.  We also present a sobering discussion of the 
potential limitations of these approaches which are becoming commonplace in the field of 
complex trait analysis, especially for BMI in light of large-scale consortium science. 
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Abstract 
Objective: To review progress in understanding the methods and results concerning the causal contribution 
of body mass index to health and disease. 
 
Method: In the context of conventional evidence focused on the relationship between BMI and health, we 
consider current literature on the the common, population based, genetic contribution to body mass index 
BMI and how this has fed into the developing field of applied epidemiology.  
 
Results: Technological and analytical developments have driven considerable success in identifying genetic 
variants relevant to BMI.  This has enabled the implementation of Mendelian randomization to address 
questions of causality. The product of this work has been the implication of BMI as a causal agent in a host 
of health outcomes. Further breakdown of causal pathways by integration with other omics technologies 
promises to deliver additional benefit.   
 
Conclusion:  Considerable progress has been made, though gaps remain in our understanding of BMI as a 
risk factor for health and disease. Whilst promising, applied genetic epidemiology should be considered 
alongside alternative methods for assessing the impact of BMI on health and in light of potential 
limitations which relate to inappropriate or nonspecific measures of obesity and the improper use of 
genetic instruments. 
 
 
 
 
 
Introduction 
The pandemic status of high BMI (obesity) has been attributed to the rise of an “obesogenic” environment 
which tips the balance between energy intake and energy expenditure, driving individuals towards 
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 4 
increased adiposity along environmentally determined lines (1, 2). Despite this it is important to realise 
that, within the same environment, not all individuals become overweight or obese and those that do have 
differential disease risk. In reality, a complex interplay of both genetic and environmental factors must be 
considered in order to better understand BMI and why it appears to have such a great health impact. 
Focusing on BMI specifically, whilst it is absolutely clear that there are strong and replicable associations 
between this risk factor and health, the interpretation of existing associations is not straightforward. In 
reality, a complex interplay of both genetic and environmental factors must be considered in order to 
better understand BMI as a phenotypic proxy for adiposity, why it appears to have such a great health 
impact and how this impact might be mitigated in future both at the individual and the population level.  
 
The underlying aetiology of relationships between BMI and health outcomes is clearly complex and likely 
to be heterogeneous across differing populations, apparently healthy individuals and those with disease. It 
is perhaps not surprising that efforts to counter the impact of ~2.3billion overweight, >700million obese 
and ~$100billion per annum care bill (including targeted dietary intervention (3), weight loss programmes 
(4, 5) and pharmaceutical interventions (6, 7)) have failed to deliver lasting reductions in BMI (>2yr) at least 
at the level of the population. Currently, the only effective intervention for weight reduction is bariatric 
surgery, which is costly, not favourable for the treatment of moderate obesity (8).  
 
Questions therefore remain as to why we continued to focus on BMI when we struggle to understand it as 
a measurement and fail to control or augment it at a policy or population level? More so, if we are content 
that the ease of BMI measurement is a justification for continued use, how might we gain insight into how 
and why BMI appears to be causally related to disease? In the context of conventional evidence focused on 
the relationship between BMI and health, this review aims to consider the current literature around the 
common, population based, genetic contribution to BMI/adiposity and how this has fed into the 
developing field of applied epidemiology in an effort to assess if and how the metric kg/m2 exerts a causal 
effect on health. In doing this, we will discuss the complications of measurement, complex genetic 
aetiology and idiosyncrasy of human phenotyping (and its effect on analysis and inference) before 
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 5 
attempting to suggest likely future moves for BMI research. 
 
Conventional approaches to the analysis of BMI and health 
 More than 1.9 billion adults, 18 years and older, were overweight with over 600 million obese in 2014. 
This represents the worldwide prevalence of obesity more than doubling between 1980 and 2014 and the 
consequences of this are put into morbid focus when one is reminded that raised BMI is a substantial risk 
factor for disease cardiovascular disease (which were the world leading cause of death in 2012), diabetes, 
musculoskeletal disorders and some cancers (endometrial, breast, and colon) (World Health Organisation, 
2015). The evidence for these relationships comes from a variety of sources, but importantly the relative 
simplicity of height and weight measurement has allowed for the formation and analysis of substantial 
BMI related data sets focused on these relationships.  
  
Examples of this include the Prospective Studies Consortium (able to assess observational relationships 
between baseline BMI and mortality in a collection of 57 studies delivering 894,576 participants mostly 
from Western Europe and North America(9) and an equally well sized initiative in Asian population based 
samples (including more than 1.14 million people recruited in 20 cohorts in Asia(10)) which have been able 
to give estimates as to the likely contribution of BMI variation to the risk of death and specific disease 
outcomes. Away from population specific differences hinting at the potential importance of body 
composition in BMI related effects, the relationship between BMI and mortality (with a marked 
cardiovascular component) is broadly consistent. Whilst not proven to be fully causal, these studies 
present a compelling illustration of these relationships.  
 
This type of work has not been limited to the collection of semi-focused, large-scale investigations of 
mortality and common disease outcome, but also has been undertaken in a manner targeting specific 
disease outcomes. For example, a detailed examination of UK Clinical Practice Research Datalink (CPRD, 
www.cprd.com) was able to characterize the observational associations between BMI and cancer risk for 
the 22 most common cancer sites seen in UK medical record data(11). In this work, more than 5 million 
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 6 
individual records reporting over 160000 cancers were investigated yielding evidence of association 
between BMI and 17 of 22 disease sub-types. Outside of likely confounding events driven by smoking, 
compelling association between BMI and disease risk are evident for cancers of the uterus, kidney, thyroid 
and leukaemia with more complex association signatures seen for liver, colon, ovarian breast cancers and 
together add to the growing range of non-specific disease risk alterations that appear linked to population 
based fluctuations in BMI. 
 
Outside the realm of observational epidemiology, interventional studies in the form of randomized control 
trials (RCTs) have of course been applied. The most commonly evaluated interventions for BMI involve 
modifications to diet and/or physical activity levels as implemented in both children (12, 13) and adults (5, 
14, 15, 16, 17).  There are also RCT that have tested the efficacy of pharmacological interventions, most 
often alongside behavioural changes with the most commonly tested agent being Orlistat (4, 18, 19) .  
However, the potential for pharmacological intervention is somewhat limited due to a lack of suitable 
drugs with favourable properties (20). Whilst most, although not all (12, 13), behavioural and/or 
pharmacological interventions result in a reduction in adiposity (as assessed by BMI or body weight), a 
major limitation of these studies with respect to inferring causality between BMI and health, is the lack of 
long-term follow-up, with a 12-month endpoint being typical. Therefore, the conversion of this reduction 
in BMI to a reduced incidence of disease later in life is not well evidenced. Indeed, apparently beneficial 
changes in cardiovascular risk factors, such as lipid profile and blood pressure, have been used to bolster 
conclusions regarding health benefits despite results from at least one longer-term trial suggesting that 
the assumed link between these intermediates and cardiovascular mortality may not be valid (14).  
 
In contrast to most behavioural intervention studies, RCTs of surgical intervention have had longer follow-
up periods allowing a more direct assessment of the impact of weight reduction on mortality.  The long-
term health impact results of RCTs for surgical intervention have been mixed and whilst there is evidence 
of a reduction in mortality following surgery (21, 22, 23), concerns have been raised around the potential 
for differences between surgical cases and untreated controls to complicate analyses (22). There is also no 
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 7 
assurance that the effects seen after these procedures is directly related to BMI/weight reduction, with 
short term impact of surgery being marked and arguably independent of weight(24). Furthermore, the 
cost-effectiveness of surgery depends on the patient’s level of obesity on admittance and the relative 
improvement in quality of life and health achieved subsequently (25). 
 
Taken together, whilst there is a deep literature focused on the examination of associations between BMI 
and common health outcomes within both observational and intervention designs, these approaches 
remain limited in their ability to assess the causal contribution of BMI to disease. Observational studies 
have been undertaken at scale, but retain the conventional limitations to inference in confounding, bias 
and reverse causation and although trials of BMI intervention are conceptually more inceptive, limitations 
to the interventions themselves and the ability to alter BMI hamper the interpretation of long term health 
implications. 
 
Genetic contributions to BMI 
Common form obesity, assessed simply by BMI level and which does not segregate in families, has a 
multifactorial basis. Individuals may carry any number of common genetic variants which contribute to 
variation in BMI at the level of the population, but most of these exert only small effects on adiposity. 
Genomewide association studies (GWAS) employ a hypothesis-free approach to identify variants 
consistently associated with complex traits (26) and use genotyping chips with the ability to score 
hundreds of thousand to millions of single nucleotide polymorphisms (SNPs) positioned across the entire 
genome. This approach has revolutionised the search for genetic associations and the interrogation of the 
common disease/common variant hypothesis specifically (27) and in the case of BMI, the first real progress 
in the application of GWAS approaches came with a study of just under 40,000 participants and from an 
initial search for type 2 diabetes loci (28). This work identified a locus with common variants reliably 
associated with BMI where carriers of two copies of the minor allele at FTOrs9939609 were on average 3kg 
heavier than the major allele carriers (29). Immediately after this first wave of GWAS analyses, it was 
acknowledged that substantially larger sample sizes, greater genomic coverage through advanced 
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 8 
reference panel use and imputation (30) and more rigorous discovery and replication phases through 
extensive consortia derived meta-analysis were needed to fully explore the common genetic contribution 
to complex traits like BMI (31, 32). The most recent of these involves 125 independent cohort studies and 
totalling nearly 340,000 participants and has brought the list of confirmed associated genetic variants to 
97 (Figure 1) (33).   
 
Despite the recent success in identifying and verifying almost 100 loci with confirmed BMI association, 
together they only explain in the region of 2.7% of the phenotypic variance in BMI (33).  Even with the 
addition of these new associated genetic variants, it is evident that although each new (bigger) GWMA 
offers new biological insight through novel gene discovery, the newly discovered associations are the 
product of larger studies and not larger effects (Figure 2). Saving the scaling up of population based 
sequencing initiatives with the capacity to score rare variants(34), the next steps are therefore to make use 
of the variants we have to try to understand the effects of BMI. Importantly even small genetic effects are 
potentially useful for this in the correct conditions and the development of MR has given utility to the “so 
what” gene variant associations GWAS is efficient at capturing. 
 
Applied genetic epidemiology and Mendelian randomisation 
Developments in the genetics of obesity have opened up a new avenue of investigation to researchers 
interested in dissecting the relationship between BMI and health – Mendelian randomisation (MR). In 
contrast to direct measurement, germline genotypes reliably associated with risk factors can act as proxy 
measurements for risk factors offering several advantages: Genotypes are relatively easy to measure, are 
stable through time, are largely immutable and are not correlated with confounding factors as a result of 
the mechanisms of Mendelian inheritance(35, 36). An alternative approach to the analysis of BMI is 
therefore to use genetic predictors to act as proxies of the feature (or exposure) one is concerned with in 
order to help investigate causality(37, 38, 39)(Figure 3A&B). In MR, genetic variation fulfils the role of an 
instrumental variable (40) where the presence of variance in BMI explained by genotype is orthogonal to 
confounding factors and where genotype is assumed only to exert effect on health outcome through BMI. 
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 9 
Whilst these assumptions are clearly open to challenge (through pleiotropy and other phenomena 
discussed at the end of this review), this approach provides an important contribution to the weight of 
evidence that may exist around a given epidemiological association. It is important to note that applied 
genetic epidemiology and MR is just one approach to the assessment of causality outside of RCTs(41). 
 
The first application of MR to BMI followed rapidly on from the discovery of FTO(rs9939609) and examined 
10 metabolic traits.  Authors of this study concluded that the FTO genotype was associated with metabolic 
traits to an extent entirely consistent with its effect on BMI although power limitations meant causal 
relationships could only be confirmed for fasting insulin, glucose, triglycerides and lower high-density 
lipoprotein cholesterol (HDL-C) (42).  By exploiting the ability of genetic variants to model lifetime 
exposure, researchers have also been able to explore the potential long-term effects of increased adiposity 
on health. To date, MR studies using BMI-associated variants have provided evidence of a causal effect of 
greater adiposity on a number of indicators of reduced cardiovascular health, including increased blood 
pressure (43), increased fasting glucose and insulin (44), decreased HDL-C (44) and increased systemic 
inflammation (45).  Causal inference with respect to complex diseases is challenging however, a causal role 
for increased adiposity has been evidenced for type 2 diabetes T2D) (44) and ischaemic heart disease (IHD) 
(46).  There are also examples of MR being applied to outcomes and traits beyond the classical 
cardiometabolic outcomes, including mental health (47, 48), childhood asthma (49), bone mass in 
childhood (50), uric acid (51), cancer (52) and trans-generational effects such as foetal over nutrition (40). 
 
As well as these simple investigations of the causal impact of BMI on health-related factors, bidirectional 
assessments (39) have also been undertaken (Figure 3C).  For example, exploring the relationship between 
the acute phase reactant C-reactive protein (CRP) and BMI, bidirectional MR has been used to exploit 
variation at independent BMI and CRP associated variants to evaluate whether BMI had a causal effect on 
CRP and simultaneously variation at the CRP loci to assess whether CRP had a causal effect on BMI (53).  
This work has provided evidence implicating BMI as a causal agent in inflammation and asserting 
directionality in an otherwise unclear network of complex phenotypes (45, 54). Other cases where causal 
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association is likely to run in both directions or suitable instruments are unavailable, results may be less 
clearly interpreted. Work implicating BMI in the aetiology of activity patterns in young participants 
recently illustrated this point - whilst the impact of BMI on activity was marked and likely to be real, the 
reciprocal relationship (which is likely to be present) was not possible to either exclude or describe 
precisely (55). 
 
One of the key parts of the MR process is the referral of evidence for causal relationships generated 
through the use of genetic data back to the existing observational estimates. A good example of this and 
the potential impact of MR analyses can be seen in that of C-reactive protein and the marked differences 
in effect estimates that have been generated from observational and MR analyses with respect to effects 
on cardiovascular health outcomes(56, 57, 58, 59, 60). In this case, it is the contrast between MR derived 
and observational estimates which provides information given a lack of support for strong observational 
effects. In contrast to this, one of the paradoxically dissatisfying observations from MR analyses of BMI as 
a risk factor is the breadth of apparenlty causal associations (bar perhaps dental caries and depression and 
foetal overnutrition(61, 62, 63, 64).  
 
Blood pressure and cardiovascular health outcomes serve to illustrate this welll with both within study 
(Figure 4) and between studies(9, 43), however this is the case elswhere. Bone health(50), cancer(52), 
asthma(49), T2D(27, 44), osteoarthritis(65) have all shown some level of agreement in the associations 
delivered by the best available observational studies and MR. Indeed a novel approach to the examination 
of BMI as a causal risk factor(66) looking across a large number of possible intermediate phenotypes was 
able to chart a broad spread of BMI related effects.  This highlights one of the key problems in the analysis 
of BMI in that, unlike others so far, there seems to be an underlying causal contribution to a large number 
of health related outcomes. This therefore leaves questions as to what are the underlying pathways and 
mechanisms responsible for these apparently causal relationships flagged by the broad exposure “BMI” 
and also as to the validity of these MR tests. 
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BMI effects: breaking down pathways 
Despite the demonstration of the likely causal relationships between BMI and IHD, it is possible that 
weight itself is not the causal agent in disease, rather that there are a suite of intermediate phenotypes 
between BMI and outcome that deliver risk.  Work not dissimilar to that originally published exploring the 
downstream impact of genetic variation at the FTO locus on cardiometabolic traits (42) used multiple 
intermediate phenotypes and also the health outcomes T2D and CHD (44) to try and unpick the pathways 
of BMI effect. In a relatively large collection of European participants (4,407 T2D, 6,073 CHD, and 3,813 
stroke cases) the causal effect of a change in BMI of 1kg/m2 on fasting glucose, fasting insulin, interleukin-
6, systolic blood pressure, reduced HDL-C and low-density lipoprotein cholesterol (LDL-C) was estimated 
alongside the change in odds for disease outcome given the same exposure. This work was able to identify 
a host of intermediate risk factor associations and related this to the strongest health outcome effects 
(T2D), although additional power was needed to obtain precise estimates of BMI effect on CHD.    
 
Coming from a similar methodological approach, MR can be employed in network analyses to identify 
causal risk factors in efforts to locate refined targets for therapeutic intervention (67). Any network of 
observational associations can be explored by the use genetic variants that independently predict the 
nodes of that network. A simple exposition of this network MR approach has been applied to break down 
the association between BMI and IHD (believed to be causal from previous MR analysis (46)) through the 
use of available intermediate risk factors measured in a population and novel instruments for each of them 
that have come from new GWAS studies.  In an example of this, the Copenhagen General Population 
Study (N=71,407) and the Copenhagen City Heart Study (N=10,314) and a case-control study, the 
Copenhagen Ischemic Heart Disease Study (N=5,262), have been used to attempt to further dissect the 
BMI/IHD association using MR and causal mediation analyses (68) (Figure 5). This work suggests that it is 
likely that BMI driven elevations of non-fasting remnant cholesterol and LDL-C, elevated blood pressure 
and possibly elevated non-fasting glucose levels may contribute causally to risk of IHD.  
 
Intermediate phenotype and the “omics” revolution 
Page 11 of 30
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
Obesity
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 12
Mendelian randomization studies have generally focused on a limited number of intermediate 
phenotypes, but recent applications of omic technologies into large scale population-based studies 
present new opportunities for identifying predictive biomarkers and causal links between established 
phenotypes and disease outcomes (69, 70, 71, 72, 73, 74). This has particular gravity for the types of 
network analysis being proposed above where, the combination of large-scale genetics data (and 
successful associations) are able to provide genetic proxy measures for an equally large collection of 
pathway specific intermediate risk factors. There is of course no guarantee that use of multi-omic 
phenotype data will avoid any of the problems encountered in observational epidemiology, but in 
combination with MR approaches, there is an opportunity to undertake network MR at scale. Omic 
technologies are now generating phenotypic data at a staggering rate and the use of these data in large 
scale population-based studies is presenting new opportunity for identifying novel predictive biomarkers 
and causal links between established phenotypes and disease outcomes (75, 76, 77, 78, 79, 80).   
 
As an example of this, it is known that metabolite profiles are useful in the prediction of cardiometabolic 
disease (81, 82), but that their role as modifiable targets for intervention or causal mediators of disease 
risk remains unclear. It is also known that many metabolites have substantial heritability and that it is 
possible to find robust associations between genetic genetic variation and the same metabolite features 
(83, 84). Together, it is then possible to examine the causal role of risk factors (in this case BMI) in the 
formation of metabolomics profiles(85) and then in a second stage (currently not applied to BMI 
systematically) to consider the causal role of those BMI driven metabolites in disease outcomes.  This is a 
process termed two-step MR(69) and when applied across multiple collections with measurements of BMI, 
intermediate phenotypes (such as metabolites) and health outcomes, has the potential to informatively 
reduce the omics measure data space (to a set of anchoring genetic variants(39)) and to breakdown causal 
pathways to disease. 
 
Challenges and limitations in the causal analysis of BMI 
(i) Measurement – the idiosyncrasy of human phenotyping 
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The options available to both clinicians and researchers for measuring adiposity are many and varied.  
They range from simple indices of body weight for stature (e.g. BMI as focused on here) to detailed 
imaging protocols using magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, DXA 
and electron microscopy.  As well as permitting the differentiation of body fat compartments relevant to 
health, such as subcutaneous versus visceral fat, such advanced technologies as combined positron 
emission tomography (PET)-CT, allow even finer resolution such that quantities of brown fat (containing 
mitochondria-rich brown adipocytes) can be measured.   
 
The statistical construct that is BMI (weight(kg)/height(m)2) was first proposed as an index of relative 
bodyweight by Adolphe Quetelet in 1842 (86).  Promoted more formally in 1972, BMI was suggested to be 
the optimum derivation for weight given stature based on the fact that, in a population of healthy men 
aged 18 to 60 years this index had lowest correlation with height and the highest correlation with 
measures of body fatness(87).  Perhaps surprisingly, considering the technological advances of recent 
years, a recent commentary on the evolution of BMI came to much the same conclusion as that of Keys 
over forty years ago – that BMI is “a robust, useful and surprisingly accurate measure of fatness in ‘healthy’ 
adults” (88). 
 
However, there remain two serious limitations of BMI as a measure of adiposity that are likely to hinder 
causal analyses.  Firstly, there is the apparent inability of BMI to adequately describe body composition 
and related to the specific characteristics of different subgroups of the population.  Comparisons of BMI 
both with alternative indices of body weight such as waist circumference, and with MRI and DXA derived 
measures of body composition have shown that BMI fails to discriminate well between major contributors 
to body composition. For example, studies have shown that short and tall individuals and those from 
different ethnicities have similar but not identical body compositions (89, 90). This type of limitation has a 
bearing on the generalisability of BMI as a measure and has driven the development of both alternative 
measures of adiposity, such as a body shape index (ABSI)(91) and modifications to BMI itself, for example, 
by optimising the power term for height to minimise its influence (92).   
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Secondly, BMI is clearly not specific.  Whilst the correlation of BMI with health outcomes is undeniable, the 
biological interpretation of these relationships is complex.  This problem was rather eloquently described 
by Wells who stated “Paradoxically, it seems that the various limitations of BMI as a specific index of 
adiposity may also be its strengths as a composite index of cardio-metabolic risk” (88).  But this concept of 
BMI as a “composite index of risk” is what makes its use in causal analyses so challenging. It is of course not 
impossible to consider the utility of specific genetic variants or collections thereof to help dissect more 
specific components of BMI, though this has not been systematically undertaken to date. 
 
(ii) Undertaking MR - don’t trust your genetic proxies 
Statistical power, correlation between genetic variants (linkage disequilibrium (LD)), the non-specificity of 
genetic effects (pleiotropy), developmental plasticity (or “canalization”(93)) and population stratification 
have all been recognised as potential limitations to the MR approach(38). However, it has become possible 
to assess and overcome issues of statistical power, LD and population stratification through the 
combination of large data sets which are based in homogeneous population based collections and that use 
independent genetic variants for analyses. Canalisation and pleiotropy remain potentially serious 
limitations. The former of these has yet to really escape the bounds of theory and if present, may only act 
to nullify genetic associations before they are found. On the other hand, pleiotropy and more generally the 
blind use of biologically complex genetic variation (and potentially large collections of complex genetic 
proxies from GWAS studies) remains one of the real challenges to these applied approaches.  
 
It is becoming increasingly clear that there are important potential complications in the formation of 
genetic proxy measures for MR studies. Through either the analysis of complex or derived phenotypic 
outcomes which can generate genetic associations which are driven by artefactual biases(94) or just the 
presence of complex biological underpinnings, the chosen genetic variation for MR studies may bring just 
as many complications as they appear to avoid. In circumstances where well-characterised, candidate 
driven and biologically understood genetic variants as proxy measures (relied upon in previous MR studies 
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derived from smaller scale genetic association studies) are unavailable, but where extremely large GWAS 
consortia yield apparently reliable association signals, it is tempting to use exhaustive lists of genetic risk 
factor in a genetic risk scores to undertake MR analyses (95).  
 
Taking the example of educational attainment (a complex, biologically distal and poorly measured 
phenotype not dissimilar to BMI), a large-scale GWAS identified three genetic variants reliably correlated 
with education (96) but these signals represent less than a tenth of the expected difference between girls 
and boys in educational attainment (97). Faced with the lack of a strong genetic proxy for substantive MR 
study, an alternative strategy is to generate composite genetic proxy measures from collections of 
genomewide data (easily done through blind application of refined software interfaces such as PLINK 
(98)). In this example specifically, a composite genetic proxy measure for educational attainment can 
explain up to ~3% of the variance in this exposure would therefore be a valuable tool for MR studies 
focused on compelling hypotheses such as the impact of education on income/lifetime earning ability.   
 
However, the formation of genetic proxy measures in this way can have complex flaws. Through the 
combined impact of genetic contributions from many different biological pathways and the possible 
biasing effects of pleiotropy, the use of genomewide proxy measures can produce effect estimates that 
are biased towards the confounded observational estimates MR is attempting to avoid. Furthermore, with 
the expansion of GWAS study sample size and power and the consequent discovery of increasingly distal 
contributions to outcome variance, looks set to introduce these complications even in the presence of 
apparently robust genetic association discoveries. The expansion of genetic association consortia for the 
analysis of BMI is now spilling way over n=300000 and with targets of up to n=1000000 in a single meta-
analysis, the abundance of genetic proxy measures for BMI is set to grow. It is therefore with these 
limitations in mind that we should approach the use of novel findings that carry with them as much 
complication as clarification.  
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This is not to remove applied genetic epidemiology and MR as a logical extension to the analysis of causal 
relationships, rather to suggest that in an era of proliferation for genetic analysis, we should remain 
sceptical of the performance of any one analysis type. Triangulation of evidence should be sought where 
possible and MR viewed as a valuable contributor rather than a sole answer(37, 38). What is clear is that the 
success of MR and its move to mainstream analysis should not become the worst enemy of this approach. 
Furthermore, the growing presence of high quality functional biological data to help understand genetic 
associations and novel statistical approaches(99) to undertaking MR will help to relieve some of the 
problems mentioned above. 
 
Conclusion 
This review has considered major contributions to non-genetic approaches to assessing the causal impact 
of BMI on human health and current knowledge concerning the common, population based, genetic 
contribution to BMI and how this has fed into the developing field of applied epidemiology. We have 
revised complications of complex genetic aetiology and phenotypic measurement, and considered 
potential development and application of multiple omic data sources to help unpick the largely 
misunderstood relationships between BMI and human health and disease. Lastly, we have brought to 
attention the importance of appropriate use of applied genetic analyses in that whilst potentially complex, 
the ability to de-confound and add clarity to the prevailing weight of evidence is a superb possibility in 
suitable conditions.  
 
Obesity and adiposity, measured principally via the faithful stand-in BMI, is of course a major risk factor 
when considering variance in risk for all sorts of health outcomes. There have now been a series of 
established study designs (prospective observational studies and MR analyses in particular) which have 
supported the notion of BMI as a causal agent in the formation of disease risk. For any given patient, 
however, it is unlikely to be the label “33kg/m2” that causes morbidity or mortality. Understanding the 
detailed routes from the biology reported (on average) by BMI to disease by employing new measurement 
techniques and through advanced causal analysis methods will be crucial for future preventative medicine. 
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Combinatorial investigations incorporating multi-omic examination of patients going through radical 
changes in BMI via surgical intervention, population based analyses of BMI affect through MR and analyses 
aimed at identifying modifiable risk factors able to modify exposure will be essential to the future 
breakdown and understanding of how BMI exerts a causal effect on health.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure titles: 
 
Figure 1: 
Manhattan plot showing body mass index (BMI)-associated variants with loci identified prior to 2015 
in blue and novel loci identified by Locke et al. (33) in red. Novel loci are labelled with the nearest gene, 
and the y-axis is truncated to allow easier observation of novel associations.  This plot is reproduced from 
Locke et al. (33) with the permission of the authors. 
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Figure 2: 
The interplay between increased variance explained and diminishing marginal return as the number 
of confirmed body mass index (BMI)-associated genetic loci has increased. The single line represents 
the cumulative variance explained and the double line the marginal return, calculated as the cumulative 
variance explained divided by the number of loci (29, 33, 100, 101, 102). 
 
Figure 3:  
Mendelian randomisation; the use of genetic proxy measures of risk factors to allow causal inference. 
(A) In general, a genotype of use to this study is associated with the exposure, is independent of measured 
or unmeasured confounders and can only influence outcome via the causal effect of the exposure. 
(B) The presence or absence of association between the BMI associated genotype and disease risk (from 
existing genomewide association study data sets) give evidence that the BMI is a causal risk factor for 
disease. 
(C) Here genotype acts as a proxy measure for an exposure potentially affecting the BMI in a reciprocal 
analysis. This type of reciprocal analysis allows for a triangulation or network approach to the assessment 
of the effects of and effects on BMI.   
 
Figure 4:  
The comparison of observational and Mendelian randomisation derived estimates for blood pressure 
and ischaemic heart disease. 
(A) Linear relationships between body mass index and blood pressure derived from observational and 
Mendelian randomization analyses. Upper scatter indicates systolic blood pressure and the lower diastolic. 
Grey areas around the estimated relationships indicate 95%CI for Mendelian randomisation estimates and 
in black those for observational estimates (plot generated from analysis for (43)). Note that for this 
analysis the log of body mass index was regressed on sex, age, age squared, log(height), and an age-sex 
interaction and exponentiated to give an individual’s “relative BMI,” that is, the ratio between his or her 
actual BMI and that expected for his or her sex, age, and height. 
(B) Meta-analysis forest plots of observational and instrumental variable estimates of the relationship 
between ischaemic heart disease and body mass index. Odds ratios are for a 4kg/m2 increase in body mass 
index (plot generated from analysis for (46)). 
 
Figure 5:  
A two-step Mendelian randomization design applied to intermediate phenotype analysis in body 
mass index (BMI) and ischaemic heart disease (IHD). In Step 1 (shown in red), BMI-associated variants 
are used to estimate the causal effect of BMI on relevant intermediates.  In Step 2 (shown in green), 
variants associated with each of the intermediate traits are used to estimate the causal effect for those 
traits on IHD.   
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